anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. 2. The blood plasma of claim 1, wherein the AB0 blood group specific antibodies of the blood plasma are neutralized and/or removed. 3. The blood plasma of claim 2, comprising high amounts of blood plasma derived from donors having the blood group A, medium amounts of blood plasma derived from donors having the blood group B, and optionally low amounts of blood plasma derived from donors having the blood group AB. 4. The blood plasma of claim 3, comprising - 6 to 10 parts of blood or blood plasma derived from donors having the blood group A, - 1 to 3 parts of blood or blood plasma derived from donors having the blood group B, - 0.0 to 1.5 parts of blood or blood plasma derived from donors having the blood group AB, - substantially no blood or blood plasma derived from donors having the blood group 0. 5. The blood plasma of any one of the foregoing claims in liquid, frozen, or dried state. 6. The blood plasma of claim 5 in lyophilized or spray-dried form. 7. The blood or blood plasma of any one of the foregoing claims having pharmaceutically acceptable adjuvants, such as stabilizers and anticoagulants. 8. The blood or blood plasma of any one of the foregoing claims which blood plasma was subjected to a treatment for virus inactivation. 9. A process of preparing the blood or blood plasma of claim 1 comprising the steps of - pooling blood or blood plasma of donors having the blood groups A, and B, - optionally admixing blood or blood plasma of donors having the blood group AB, optionally producing plasma from the blood or blood plasma pool, - neutralizing and/or removing AB0 blood group specific antibodies. 10. The process of claim 9 further comprising the step of spray-drying or lyophilizing the plasma.
Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
The mechanism underlying allodynia/hyperalgesia caused by dental pulpitis has remained enigmatic. This investigation endeavored to characterize the influence of the purinergic receptor P2X3 on pain caused by experimental pulpitis and the mechanism involved. An experimental model of irreversible pulpitis was produced by the drilling and exposure of the dental pulp of the left upper first and second molars in rats, followed by measuring nociceptive responses in the oral and maxillofacial regions. Subsequently, neuronal activity and the expression of P2X3 and pertinent cytokines in the trigeminal ganglion (TG) were meticulously examined and analyzed. Histological evidence corroborated that significant pulpitis was produced in this model, which led to a distinct escalation in nociceptive responses in rats. The activation of neurons, coupled with the upregulated expression of c-fos, P2X3, p-p38, TNF-α and IL-1β, was identified subsequent to the pulpitis surgery within the TG. The selective inhibition of P2X3 with A-317491 effectively restrained the abnormal allodynia/hyperalgesia following the pulpitis surgery and concurrently inhibited the upregulation of p-p38, TNF-α and IL-1β within the TG. These findings suggest that the P2X3 signaling pathway plays a pivotal role in instigating and perpetuating pain subsequent to the induction of pulpitis in rats, implicating its association with the p38 MAPK signaling pathway and inflammatory factors.
The invention relates to allicin thrombolytic tablets, which are current novel products prepared from garlic. Garlic contains ajoene and sulfide, and can be used for preventing the forming of thrombus. Thrombosis is a pathologic phenomenon of human cardiocerebral vessels. Thrombosis is divided into coronary artery thrombosis and cerebral thrombosis. The two thromboses can cause various cardiocerebral diseases such as cerebral stroke and myocardial infarction. The tablets provided by the invention provide substantial treatment effect against the diseases.
Methods and compositions for treating or preventing immune -mediated conditions are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of a BLyS/APRIL antagonist (e.g. TACI-lg) in combination with an antagonist of the CD40 pathway (e.g. an anti-CD40 or an anti-CD154 antibody). The combination of the BLyS/APRIL antagonist and the antagonist of the CD40 pathway promotes a desired therapeutic response. The BLySAPRIL antagonist and the CD40 pathway antagonist may be administered simultaneously or sequentially as a single pharmaceutical composition or as separate pharmaceutical compositions, each comprising a BLySAPRIL antagonist and an antagonist of the CD40 pathway. Methods of the invention find use in treating or preventing a variety of immune -mediated conditions including, for example, treating or preventing transplant rejections or graft-versus -host disease or reducing the level of an immune response or reducing the level of immunoglobulins in a subject in need thereof.
The research involves the synthesis of a series of new pyridine analogs 5(i-x) and their evaluation for anti-epileptic potential using in silico and in vivo models. Synthesis of the compounds was accomplished by using the Vilsmeier-Haack reaction principle. AutoDock 4.2 was used for their in silico screening against AMPA (-amino-3-hydroxy-5-methylisoxazole) receptor (PDB ID:3m3f). For in vivo testing, the maximal electroshock seizure (MES) model was used. The physicochemical, pharmacokinetic, drug-like, and drug-score features of all synthesized compounds were assessed using the online Swiss ADME and Protein Plus software. The in silico results showed that all the synthesized compounds 5(i-x) had 1-3 interactions and affinities ranging from -6.5 to -8.0 kJ/mol with the targeted receptor compared to the binding affinities of the standard drug phenytoin and the original ligand of the target (P99), which were -7.6 and -6.8 kJ/mol, respectively. In vivo study results showed that the compound 5-Carbamoyl-2-formyl-1-[2-(4-nitrophenyl)-2-oxo-ethyl]-pyridinium gave 60% protection against epileptic seizures compared to 59% protection afforded by regular phenytoin. All of them met Lipinski's rule of five and had drug-likeness and drug score values of 0.55 and 0.8, respectively, making them chemically and functionally like phenytoin. According to the findings of the studies, the synthesized derivatives have the potential to be employed as a stepping stone in the development of novel anti-epileptic drugs.
The invention relates to an application of Cyr61 in a psoriasis medicine and belongs to the field of biological medicine. The invention also relates to an application of a Cyr61 inhibitor in the preparation of a psoriasis medicine. By the utilization of a real-time quantitative PCR method, expression of Cyr61 at a skin damage position of a patient with psoriasis is analyzed, and a specific Cyr61siRNA sequence interference experiment is adopted. It is verified that Cyr61 molecules participate in the generation of psoriasis: inflammatory factors in skin lesion area of psoriasis patients can upregulate the expression of keratin (K6) by increasing Cyr61 molecule secretion of keratinocytes, which results in the promoting hyperproliferation and incomplete differentiation of keratinocytes, and then leads to psoriasis skin lesion. After blockade of Cyr61 function with anti Cyr61 specific neutralizing antibodies, the expression of K6 can be reduced and skin lesion and pathology of psoriasis are alleviated. Thus, Cyr61 does participates in the generation of psoriasis and is also an important therapeutic target.
The invention relates to the use of PP2A/B.gamma. and to the use of a PP2A  phosphatase comprising the PP2A/B.gamma. subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The invention also discloses biallelic markers located in the gene encoding PP2A/B.gamma. and their use for diagnosing mental disorders.
Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
The present invention provides a novel scientific approach to determine whether a compound has anti-inflammatory activity. In particular, the novel assays allow the screening of compounds for the purposes of prophylactic and therapeutic use in treating or ameliorating the symptoms of T-cell, macrophage or neutrophil mediated diseases in mammals. In particular, the invention is based on the measurement of the capacity of a substance being an oil or fat, an alcoholic extract of an oil or fat, a biologically active component of an oil or a fat, or a preparation comprising an oil or fat, to suppress the activity of T-cells, macrophages or neutrophils in humans or animals in response to chemical and/or biological agents that activate these cell types. Measurements are made either in vivo (eg in mice) or in an in vitro preparation of human T-cells, macrophages or neutrophils, or a cell line derived therefrom. The substance is, in particular, emu oil or an ethanolic extract thereof. Therapeutic compositions and methods are also disclosed.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to combustiology and can be used in preparing donor skin sites before drawing grafts in skin grafting. That is ensured by introduction of ozonised physiologic saline with ozone concentration 160-200 mcg in subcutaneous fat of a donor site. Introduction is performed 10-15 minutes prior to cutting the grafts in amount 150-200 ml. ^ EFFECT: method ensures considerable reduction of time of donor wound epithelisation due to improved microcirculation that allows reusing donor sites. ^ 1 ex
NEW MATERIAL:The compound of formula (X, Y and Z are H, halogen alkyl or lower alkoxy; provided that X, Y and Z are not H at the same time). EXAMPLE:4-Chloroinnamoylsalicylic acid. USE:Medicine effective to suppress the immediate allergosis by oral administration. PROCESS:The objective compound of formula can be prepared by the direct condensation of a substituted cinnamic acid and salicylic acid using dicyclohexyl carbodiimide. The substituted cinnamoyl group of the compound of formula is e.g. 2-methoxycinnamoyl, 2-chlorocinnamoyl, 3,4-dimethoxycinnamoyl, etc. The compound of formula can be prepared preferably by the Schotten-Baumann reaction of the substituted cinnamoyl chloride with salicylic acid as well as the method described above.
FIELD: medicine, oncology. SUBSTANCE: method involves ligation of proximal region of a. pancreatoduodenalis superior and catheterization of its distal region. Contrasting substance is administrated into distal region of artery. After identification of total venous collector ligation is carried out up to 50% of its venous outflow. Then intra-arterial regional monochemotherapy with 5-fluorouracil is carried out. Cytostatic is administrated during operation and in post-operative period. EFFECT: improved results of treatment of patients with malignant tumor, among them nonoperative pancreas tumors. 2 ex
Objective.This study develops a deep learning (DL) method for fast auditory attention decoding (AAD) using electroencephalography (EEG) from listeners with hearing impairment (HI). It addresses three classification tasks: differentiating noise from speech-in-noise, classifying the direction of attended speech (left vs. right) and identifying the activation status of hearing aid noise reduction algorithms (OFF vs. ON). These tasks contribute to our understanding of how hearing technology influences auditory processing in the hearing-impaired population.Approach.Deep convolutional neural network (DCNN) models were designed for each task. Two training strategies were employed to clarify the impact of data splitting on AAD tasks: inter-trial, where the testing set used classification windows from trials that the training set had not seen, and intra-trial, where the testing set used unseen classification windows from trials where other segments were seen during training. The models were evaluated on EEG data from 31 participants with HI, listening to competing talkers amidst background noise.Main results.Using 1 s classification windows, DCNN models achieve accuracy (ACC) of 69.8%, 73.3% and 82.9% and area-under-curve (AUC) of 77.2%, 80.6% and 92.1% for the three tasks respectively on inter-trial strategy. In the intra-trial strategy, they achieved ACC of 87.9%, 80.1% and 97.5%, along with AUC of 94.6%, 89.1%, and 99.8%. Our DCNN models show good performance on short 1 s EEG samples, making them suitable for real-world applications. Conclusion: Our DCNN models successfully addressed three tasks with short 1 s EEG windows from participants with HI, showcasing their potential. While the inter-trial strategy demonstrated promise for assessing AAD, the intra-trial approach yielded inflated results, underscoring the important role of proper data splitting in EEG-based AAD tasks.Significance.Our findings showcase the promising potential of EEG-based tools for assessing auditory attention in clinical contexts and advancing hearing technology, while also promoting further exploration of alternative DL architectures and their potential constraints.
The invention provides application of a nuclear receptor coactivator 4 serving as a target spot in screening and preparing a medicine for treating polycystic ovary syndrome ovulation disorder. The invention also provides application of the reagent for detecting the nuclear receptor coactivator 4 in preparing a kit for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides application of the nuclear receptor coactivator 4 in preparing a marker for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides application of the nuclear receptor coactivator 4 serving as a diagnostic marker in preparing a kit for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides an interfering RNA, the nucleotide sequence of which is 5'-GACCUUAUUUAUCAGCUUATT-3'. The present invention has found that NCOA4 can improve ERK1/2 phosphorylation inhibition by androgens and C/EBP beta expression reduction.
Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition caused by decreased plasma and tissue levels of alpha-1 antitrypsin (AAT) that can lead to serious lung and liver disease in children and adults. AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detection and biomarkers for predicting outcomes are needed to improve patient outcome. Currently, the only approved pharmacological therapy is augmentation therapy, which can delay the progression of emphysema. However, alternative strategies such as gene therapy, induced pluripotent stem cells, and prevention of AAT polymerization inside hepatocytes are being investigated. This review aims to summarize and update current knowledge on AATD, identify areas of controversy, and formulate questions for further research.
Subjects will participate in 4 study day visits that will be scheduled about 1- week apart. During the first study visit, the investigators will compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological stimulation of sweating (using a stationary bicycle). During the second study visit, the investigators will collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) and also the upper surface of the thigh (near the knee). During the third study visit, the investigators will collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist). During the fourth study visit, the investigators will collect a sweat sample following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) and a blood sample (about one teaspoon) from the other arm. After blood and sweat collection, participants will consume 400 mg (two tablets) of ibuprofen. The investigators will then collect blood and sweat from 30 minutes, 2 hours and 4 hours after participants consume the ibuprofen.
The invention pertains to the traditional Chinese medicine field and the field of the preparative technique thereof and particularly discloses a traditional Chinese medicine used for treating sciatica and a preparation method thereof. The traditional Chinese medicine is prepared with the following crude drugs: angelica, rhizoma atractylodis, radix aconite, rhizoma et radix notopterygii, boswellia carteri, cortex eucommiae, dendrobium, wooly datchmanspipe herb, radices gentianae macrophyllae, rehmanniae vaporata, radix achyranthis bidentatae, pericarpium citri reticulatae, myrrh, wu chia pee, phellodendron, gamdir vine and safflower. The crude drugs are put into a decoction vessel and water, white spirit and brown sugar are added to form a mixture; the mixture is decocted to boil and the preparation is completed by taking the liquid medicine after cooling. The traditional Chinese medicine aims at the causes of the illness and prepared by composing prescriptions according to the treatment based on syndrome differentiation of the traditional Chinese medicine of China; the traditional Chinese medicine has a reasonable compatibility and has the efficacies of expelling wind, clearing away cold, promoting blood circulation to remove meridian obstruction, stretching or tendon-relaxing and relieving pain. The traditional Chinese medicine also has a high cure rate and after using the medicine, the disease is not easy to recur. The oral solution made of the traditional Chinese medicine has a balanced active ingredient and benefits the absorption of the patients, thereby improving the curative effect.
An improved method (process) is provided to treat herpes,  pseudomonas, staphylococcus  (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes,  pseudomonas , staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt surfactant, a skin protectant and an alcohol. The quaternary ammonium salt surfactant can comprise benzalkonium halide, preferably benzalkonium chloride. The skin protectant can comprise Allantoin. The alcohol can serve as a pain reliever and can comprise benzyl alcohol. The medicinal composition can also include other compounds, additives, herbal extracts and/or carriers. Desirably, the medicinal composition is maintained on the infected regions until external symptoms and physical manifestations of the symptoms resulting from herpes,  pseudomonas , hepatitis, or staph substantially disappear from the infected regions.
BACKGROUND: The prognostic impact of functionally significant coronary artery disease, as assessed with quantitative flow ratio (QFR), in patients with severe aortic stenosis treated with transcatheter aortic valve replacement is unknown.
METHODS: This is a retrospective study with blind analysis of angiographic data, enrolling consecutive patients with severe aortic stenosis treated with transcatheter aortic valve replacement at 4 Italian centers. None of the patients enrolled received pre-transcatheter aortic valve replacement or concomitant coronary revascularization, either for the absence of significant coronary stenoses or by clinical decision. Visual estimation of diameter stenosis and QFR analysis were performed in all coronary arteries. The end point was all-cause mortality at a 3-year follow-up.
RESULTS: A total of 318 patients were enrolled. At visual estimation, 140 patients (44%) presented a diameter stenosis ≥50% in at least 1 coronary artery, whereas 78 patients (24.5%) had at least 1 vessel with QFR <0.80 and, therefore, included in the positive QFR group. Overall, 69 (21.7%) patients died during the follow-up. In the Kaplan-Meier analysis, patients with positive QFR experienced significantly higher rates of death during follow-up compared with those without (51.1% versus 12.1%; P<0.001), whereas no significant difference was evident in terms of death between patients with or without significant coronary artery disease according to angiographic evaluation (24.3% versus 19.7%; P=0.244). In a multivariate regression model, positive QFR was an independent predictor of all-cause death during follow-up (hazard ratio, 5.31 [95% CI, 3.21-8.76]).
CONCLUSIONS: Coronary QFR can predict mortality in patients with severe aortic stenosis treated with transcatheter aortic valve replacement without revascularization.
Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
Bioabsorbable sutures can improve the medical functions of existing non-absorbable sutures, and may produce new medical effects, and are expected to become a new generation of medical degradable materials. In this study, the cytocompatibility of triclosan coated polyglactin910 sutures (CTS-PLGA910) was analyzed and different concentrations of sutures were prepared. The effects of sutures on the cytotoxicity and cell proliferation of HUVEC were studied by CCK-8 assay. The hemolysis, total antioxidant capacity (T-AOC) activity and nitric oxide (NO) content were investigated to improve the blood compatibility of sutures. The results showed that the hemolysis rate of CTS-PLGA910 was less than 5%. After treatment on HUVEC cells for 48 and 72 h, there was no significant change in NO content in CTS-PLGA910 groups compared with the control group, while T-AOC activity and antioxidant capacity were significantly increased in medium and high dose groups. In summary, the blood compatibility and cell compatibility were significantly improved, which provided a basis for the clinical application of sutures in the future.